

Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr® Bioconjugation Platform

Curapath and Cristal Therapeutics partner to bring CliCr® bioconjugation to targeted nanoparticle delivery, advancing next-generation therapies.

PATERNA, VALENCIA, SPAIN, November 26, 2025 /EINPresswire.com/ --

Curapath, a leading innovator in the development and manufacturing of polymer and lipid-based drug delivery systems, and Cristal Therapeutics

Curapath, a biotech company developing innovative conjugation technologies, today announced they entered into a co-exclusive license agreement for the

CliCr® bioconjugation platform. The platform offers a powerful and scalable solution for efficient, site-specific and stable conjugation of biomolecules, addressing a critical challenge in drug development and targeted drug delivery to extrahepatic tissues.



Under the agreement, [Curapath](#) will be the exclusive manufacturer and distributor (outside) of Curapath's CliCr® bioconjugation platform for the delivery of nucleic acids via targeted polymeric and lipid nanoparticles (LNPs). [Cristal Therapeutics](#) and Curapath will both have the right to grant sublicenses in this exciting and rapidly expanding field.

Dr. Juan Carlos Rodríguez, CEO of Curapath, stated:

"Active targeting remains one of the greatest challenges in advanced drug delivery. By integrating Cristal Therapeutics' CliCr® platform, Curapath strengthens its leadership in next-generation delivery systems, including targeting LNPs to extrahepatic tissues. This alliance enables us to offer innovators a scalable, precise, and stable bioconjugation solution, accelerating the development of safer, more effective targeted therapies."

Dr. Juan Carlos Rodríguez, CEO of Curapath, commented:

"We are very pleased to collaborate with Curapath, a strong and leading CDMO in the LNP field. This collaboration places CliCr® in an excellent position to become the standard in

bioconjugation to nanoparticles for nucleic acid drug delivery. It is another example for the broad applicability of the CliCr® platform in therapeutic drug and diagnostic development."

The financial terms of the agreement were not disclosed.

Curapath

Curapath is a science-driven CDMO specializing in the design, development, and GMP manufacturing of advanced drug delivery systems. Curapath supports biopharma companies from early R&D through to commercial production, enabling innovation across every stage. With a strong expertise in nanoencapsulation and non-viral gene delivery, Curapath offers polymer and lipid-based nanoparticles tailored for a wide variety of payloads. From excipient synthesis to drug product formulation, the flexible service model and proprietary technologies ensure a seamless path to the clinic. Committed to quality, innovation, and collaboration, Curapath helps bring next-generation therapies to market faster.

To know more about Curapath visit: <https://curapath.com/>

Cristal Therapeutics

Cristal Therapeutics is a biotechnology company dedicated to the development of superior bioconjugates with improved therapeutic profiles for better treatment outcomes in patients. The company's proprietary CliCr® copper-free click chemistry enables site-specific, rapid, and robust conjugation of a wide variety of biomolecules. Designed to operate under mild up to even extreme conditions, CliCr® offers superior performance for applications in antibody-drug conjugates (ADCs), targeted delivery systems, diagnostics, and more. The conjugation is known for its unmatched precision, compatibility and ease of manufacturing up to and including under GMP. CliCr® enhances therapeutic product quality by minimizing impurities and strengthening conjugate stability, resulting in extended circulation, higher efficacy, and improved patient safety.

To learn more about Cristal Therapeutics visit: <https://cristaltherapeutics.com/>

Curapath

Curapath

+34 963 76 90 80

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/870112252>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

